Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2015

Open Access 01-12-2015 | Research

Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?

Authors: Nan Luo, Yin Bun Cheung, Raymond Ng, Chun Fan Lee

Published in: Health and Quality of Life Outcomes | Issue 1/2015

Login to get access

Abstract

Objective

Utility values of health states defined by health-related quality of life instruments can be derived from either direct valuation (‘valuation-derived’) or mapping (‘mapping-derived’). This study aimed to compare the utility-based EQ-5D-5L index scores derived from the two approaches as a means to validating the mapping function developed by van Hout et al for the EQ-5D-5L instrument.

Methods

This was an observational study of 269 breast cancer patients whose EQ-5D-5L index scores were derived from both methods. For comparing discriminatory ability and responsiveness to change, multivariable regression models were used to estimate the effect sizes of various health indicators on the index scores. Agreement and test-retest reliability were examined using intraclass correlation coefficient (ICC). Whenever appropriate, the 90 % confidence intervals (90 % CI) were compared to predefined equivalence margins.

Results

The mean difference in and ICC between the valuation- and mapping-derived EQ-5D-5L index scores were 0.015 (90 % CI = 0.006 to 0.024) and 0.915, respectively. Discriminatory ability and responsiveness of the two indices were equivalent in 13 of 15 regression analyses. However, the mapping-derived index score was lower than the valuation-derived index score in patients experiencing extreme health problems, and the test-retest reliability of the former was lower than the latter, for example, their ICCs differed by 0.121 (90 % CI = 0.051 to 0.198) in patients who reported no change in performance status in the follow-up survey.

Conclusion

This study provided the first evidence supporting the validity of the mapping function for converting EQ-5D-5L profile data into a utility-based index score.
Literature
1.
go back to reference Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation. New York: Oxford University Press; 2007. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and Valuing Health Benefits for Economic Evaluation. New York: Oxford University Press; 2007.
2.
go back to reference Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.CrossRefPubMed Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.CrossRefPubMed
3.
4.
go back to reference Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRefPubMed Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.CrossRefPubMed
5.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedCentralCrossRefPubMed Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedCentralCrossRefPubMed
6.
go back to reference van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.CrossRefPubMed van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.CrossRefPubMed
8.
go back to reference Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.CrossRefPubMed Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202–10.CrossRefPubMed
11.
go back to reference Fayers PM, Hays RD. Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health. 2014;17(2):261–5.PubMedCentralCrossRefPubMed Fayers PM, Hays RD. Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health. 2014;17(2):261–5.PubMedCentralCrossRefPubMed
12.
go back to reference Ramos-Goñi JM, Pinto-Prades JL, Oppe M, Cabasés JM, Serrano-Aguilar P, Rivero-Arias O. Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach. Med Care. 2014 Dec 17 [Epub ahead of print]. Ramos-Goñi JM, Pinto-Prades JL, Oppe M, Cabasés JM, Serrano-Aguilar P, Rivero-Arias O. Valuation and Modeling of EQ-5D-5L Health States Using a Hybrid Approach. Med Care. 2014 Dec 17 [Epub ahead of print].
13.
go back to reference Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.PubMed Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86.PubMed
14.
go back to reference Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, et al. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat. 2007;106(3):413–8.CrossRefPubMed Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, et al. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat. 2007;106(3):413–8.CrossRefPubMed
15.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefPubMed Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefPubMed
16.
go back to reference Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89(6):1022–7.PubMedCentralCrossRefPubMed Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89(6):1022–7.PubMedCentralCrossRefPubMed
17.
go back to reference Cheung YB, Goh C, Thumboo J, Khoo KS, Wee J. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol. 2005;23(22):4936–44.CrossRefPubMed Cheung YB, Goh C, Thumboo J, Khoo KS, Wee J. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. J Clin Oncol. 2005;23(22):4936–44.CrossRefPubMed
18.
go back to reference Lee CF, Ng R, Luo N, Wong NS, Yap YS, Lo SK, et al. The English and Chinese versions of the five-level EuroQoL Group’s five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients. Support Care Cancer. 2013;21(1):201–9.CrossRefPubMed Lee CF, Ng R, Luo N, Wong NS, Yap YS, Lo SK, et al. The English and Chinese versions of the five-level EuroQoL Group’s five-dimension questionnaire (EQ-5D) were valid and reliable and provided comparable scores in Asian breast cancer patients. Support Care Cancer. 2013;21(1):201–9.CrossRefPubMed
19.
go back to reference Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, et al. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group’s 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. Qual Life Res. 2013;22(7):1745–51.CrossRefPubMed Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, et al. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group’s 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. Qual Life Res. 2013;22(7):1745–51.CrossRefPubMed
20.
go back to reference Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.PubMedCentralCrossRefPubMed Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.PubMedCentralCrossRefPubMed
21.
go back to reference Scalone L, Ciampichini R, Fagiuoli S, Gardini I, Fusco F, Gaeta L, et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual Life Res. 2013;22(7):1707–16.CrossRefPubMed Scalone L, Ciampichini R, Fagiuoli S, Gardini I, Fusco F, Gaeta L, et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual Life Res. 2013;22(7):1707–16.CrossRefPubMed
22.
go back to reference Jia YX, Cui FQ, Li L, Zhang DL, Zhang GM, Wang FZ, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23(8):2355–63.CrossRefPubMed Jia YX, Cui FQ, Li L, Zhang DL, Zhang GM, Wang FZ, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23(8):2355–63.CrossRefPubMed
23.
go back to reference Pan CW, Sun HP, Wang X, Ma Q, Xu Y, Luo N, et al. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual Life Res. 2015;24(7):1767–74.CrossRefPubMed Pan CW, Sun HP, Wang X, Ma Q, Xu Y, Luo N, et al. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual Life Res. 2015;24(7):1767–74.CrossRefPubMed
24.
go back to reference Pattanaphesaj J, Thavorncharoensap M. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health Qual Life Outcomes. 2015;13:14.PubMedCentralCrossRefPubMed Pattanaphesaj J, Thavorncharoensap M. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health Qual Life Outcomes. 2015;13:14.PubMedCentralCrossRefPubMed
25.
go back to reference Cella D. FACIT manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Evanston: Center on Outcomes, Research and Education; 1997. Cella D. FACIT manual: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Evanston: Center on Outcomes, Research and Education; 1997.
26.
go back to reference Ng R, Lee CF, Wong NS, Luo N, Yap YS, Lo SK, et al. Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients. Breast Cancer Res Treat. 2012;131(2):619–25.CrossRefPubMed Ng R, Lee CF, Wong NS, Luo N, Yap YS, Lo SK, et al. Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients. Breast Cancer Res Treat. 2012;131(2):619–25.CrossRefPubMed
27.
go back to reference Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445–53.CrossRefPubMed Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445–53.CrossRefPubMed
28.
go back to reference Badia X, Roset R, Herdman, M, Kind P. A comparison of GB and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making. 2001; 21(1): 7-16. Badia X, Roset R, Herdman, M, Kind P. A comparison of GB and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making. 2001; 21(1): 7-16.
29.
go back to reference Cheung YB, Thumboo J, Goh C, Khoo KS, Che W, Wee J. The equivalence and difference between the English and Chinese versions of two major, cancer-specific, health-related quality-of-life questionnaires. Cancer. 2004;101(12):2874–80.CrossRefPubMed Cheung YB, Thumboo J, Goh C, Khoo KS, Che W, Wee J. The equivalence and difference between the English and Chinese versions of two major, cancer-specific, health-related quality-of-life questionnaires. Cancer. 2004;101(12):2874–80.CrossRefPubMed
30.
go back to reference Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, et al. Do English and Chinese EQ-5D versions demonstrate measurement equivalence? An exploratory study. Health Qual Life Outcomes. 2003;1:7.PubMedCentralCrossRefPubMed Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, et al. Do English and Chinese EQ-5D versions demonstrate measurement equivalence? An exploratory study. Health Qual Life Outcomes. 2003;1:7.PubMedCentralCrossRefPubMed
31.
go back to reference Gao F, Ng GY, Cheung YB, Thumboo J, Pang G, Koo WH, et al. The Singaporean English and Chinese versions of the EQ-5D achieved measurement equivalence in cancer patients. J Clin Epidemiol. 2009;62(2):206–13.CrossRefPubMed Gao F, Ng GY, Cheung YB, Thumboo J, Pang G, Koo WH, et al. The Singaporean English and Chinese versions of the EQ-5D achieved measurement equivalence in cancer patients. J Clin Epidemiol. 2009;62(2):206–13.CrossRefPubMed
32.
go back to reference Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34(1):215–20.CrossRefPubMed Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34(1):215–20.CrossRefPubMed
33.
go back to reference Ramasundarahettige CF, Donner A, Zou GY. Confidence interval construction for a difference between two dependent intraclass correlation coefficients. Stat Med. 2009;28(7):1041–53.CrossRefPubMed Ramasundarahettige CF, Donner A, Zou GY. Confidence interval construction for a difference between two dependent intraclass correlation coefficients. Stat Med. 2009;28(7):1041–53.CrossRefPubMed
34.
go back to reference Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.CrossRefPubMed Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.CrossRefPubMed
35.
go back to reference Myles PS, Cui J. Using the Bland-Altman method to measure agreement with repeated measures. Br J Anaesth. 2007;99(3):309–11.CrossRefPubMed Myles PS, Cui J. Using the Bland-Altman method to measure agreement with repeated measures. Br J Anaesth. 2007;99(3):309–11.CrossRefPubMed
36.
go back to reference Cheung YB, Tan LC, Lau PN, Au WL, Luo N. Mapping the eight-item Parkinson’s Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Qual Life Res. 2008;17(9):1173–81.CrossRefPubMed Cheung YB, Tan LC, Lau PN, Au WL, Luo N. Mapping the eight-item Parkinson’s Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Qual Life Res. 2008;17(9):1173–81.CrossRefPubMed
37.
go back to reference Cheung YB, Luo N, Ng R, Lee CF. Mapping the Functional Assessment of Cancer Therapy-Breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12:180.PubMedCentralCrossRefPubMed Cheung YB, Luo N, Ng R, Lee CF. Mapping the Functional Assessment of Cancer Therapy-Breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12:180.PubMedCentralCrossRefPubMed
38.
go back to reference Crott R. Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):569–76.CrossRefPubMed Crott R. Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):569–76.CrossRefPubMed
Metadata
Title
Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?
Authors
Nan Luo
Yin Bun Cheung
Raymond Ng
Chun Fan Lee
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2015
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-015-0361-y

Other articles of this Issue 1/2015

Health and Quality of Life Outcomes 1/2015 Go to the issue